EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Understanding Patient and Gastroenterologist Preferences at the Time of Treatment Escalation to First‐Line Advanced Therapy in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries

Stefan Schreiber, Alissa Walsh, Peter Hur, Laura Panattoni, Brett Hauber iD, Natalie Land iD, Josh Coulter iD, Grace Gahlon, Karolina Wosik, Joseph C Cappelleri iD, Melissa Culhane Maravic, Xiang Guo und 1 weitere

United European Gastroenterology Journal · 2026-06 · 14 (5)

DOI: 10.1002/ueg2.70229 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 02.06.2026. Verfasst von Stefan Schreiber und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Patient Preference, Gastroenterologists. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With guidelines recommending earlier advanced therapy (AT) use after 5‐ASA failure for patients with moderately‐to‐severely active ulcerative colitis (UC), it is important to explore treatment preferences at the point of escalation to first‐line AT.

Methods

A web‐based discrete choice experiment (DCE) survey was administered to AT‐naïve patients with moderately‐to‐severely active UC and gastroenterologists in 5 European countries. Treatment attributes included time until symptom improvement, probability of remission and corticosteroid‐free remission, risks of cancer, serious infection, and major adverse cardiovascular events (MACE), and mode of administration. Preference weights, relative attribute importance (RAI), and maximum acceptable risk were estimated. A latent class analysis explored preference heterogeneity.

Results

Probability of remission at 1 year was the most important attribute for patients ( N = 514; RAI = 45.3%) and gastroenterologists ( N = 397; RAI = 48.5%). Five‐year cancer risk was the second most important attribute for patients (RAI = 11.8%) and third for gastroenterologists (RAI = 10.9%). RAI of MACE was higher for patients than gastroenterologists (10.6% vs. 6.8%). Both were willing to accept risks for increased probability of remission. Latent class analysis identified 4 groups of patients and 2 groups of gastroenterologists with distinct preferences. The relative importance of efficacy was higher compared with safety in latent classes representing 80% of patients.

Conclusion

Clinical remission was most important to patients and gastroenterologists, and both were willing to accept some risk in exchange for the benefits of AT. However, some heterogeneity in preferences was observed. To support patient‐centered, guideline‐concordant care, gastroenterologists should discuss escalation to AT with patients not well‐controlled on conventional therapy, incorporating individual preferences through shared decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativePatient PreferenceGastroenterologistsHumansFemaleMaleEuropeAdultMiddle AgedRemission InductionSurveys and QuestionnairesChoice BehaviorSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

advanced therapydiscrete choice experimentgastroenterologist preferenceinflammatory bowel diseasepatient preferenceulcerative colitis

Autor:innen und Institutionen

  • Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.
  • Translational Gastroenterology and Hepatology Unit, Oxford University Hospital, Oxford, UK.
  • Pfizer Inc, New York, New York, USA.
  • Precision AQ, New York, New York, USA.
  • Pfizer Canada, Kirkland, Quebec City, Canada.
  • Pfizer Inc, Groton, Connecticut, USA.

ORCID-Profile: Brett Hauber, Natalie Land, Josh Coulter, Joseph C Cappelleri

Förderung

  • Pfizer

Zitieren

APA

Schreiber, S., Walsh, A., Hur, P., Panattoni, L., Hauber, B., Land, N., Coulter, J., Gahlon, G., Wosik, K., Cappelleri, J. C., Maravic, M. C., Guo, X., & Buisson, A. (2026). Understanding Patient and Gastroenterologist Preferences at the Time of Treatment Escalation to First‐Line Advanced Therapy in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries. United European Gastroenterology Journal, 14(5). https://doi.org/10.1002/ueg2.70229

Vancouver

Schreiber S, Walsh A, Hur P, Panattoni L, Hauber B, Land N, et al. Understanding Patient and Gastroenterologist Preferences at the Time of Treatment Escalation to First‐Line Advanced Therapy in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries. United European Gastroenterology Journal. 2026;14(5). doi:10.1002/ueg2.70229

BibTeX
@article{Schreiber2026,
  author = {Schreiber, Stefan and Walsh, Alissa and Hur, Peter and Panattoni, Laura and Hauber, Brett and Land, Natalie and Coulter, Josh and Gahlon, Grace and Wosik, Karolina and Cappelleri, Joseph C and Maravic, Melissa Culhane and Guo, Xiang and Buisson, Anthony},
  title = {Understanding Patient and Gastroenterologist Preferences at the Time of Treatment Escalation to First‐Line Advanced Therapy in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  volume = {14},
  number = {5},
  doi = {10.1002/ueg2.70229}
}
Kostenlos starten →